Diasorin S.p.a. · MIL:DIA
Diasorin — H1 2022 Earnings Presentation
17 slides from Diasorin's earnings presentation, Aug 3, 2022
Slide 1: H1 2022 Results
H1 2022 RESULTS August 3, 2022
Slide 2: Disclaimer
Disclaimer In General. This disclaimer applies to this presentation and any oral comments of any person presenting it. This document, taken together with any such oral comments, is referred to herein as the “Presentation”. This Presentation has been prepared by DiaSorin S.p.A. (“DiaSorin” or the “Co
Slide 3: Forward-looking statements
Forward-looking statements This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which DiaSorin operates and the beliefs and assumptions of the management of DiaSorin. In addition, the management of DiaS
Slide 4: Financial Highlights
Financial Highlights* Change Change Data in €/mln Q2’22 H1’22 @ current @ CER @ current @ CER Revenues 328 +31.8% +22.0% 685 +33.0% +25.1% Immunodiagnostics ex-COVID 173 +9.9% +4.3% 333 +10.0% +5.4% Molecular Diagnostics ex-COVID 50 +212.9% +178.7% 97 +170.9% +147.8% Licensed Technologies 52 n.m. n.
Slide 5: Immunodiagnostics H1 2022 key facts
H1 2022 key facts Product Development Business Development • New Simplexa™ SARS-CoV-2 Variants Direct Assay (Research • Appointment of Angelo Rago, a senior executive with a 30+ years Use Only) for the detection and discrimination of mutations associated experience in MedTech global companies, as th
Slide 6: Managerial outlook on Q2 and H1 2022 revenues
Managerial outlook on Q2 and H1 2022 revenues Total Q2 Group revenues (data in €/mln) Total H1 Group revenues (data in €/mln) Data @CER Data @CUR Data @CER Data @CUR +22% +32% +25% +33% 304 328 645 685 249 49 249 53 515 141 515 150 75 75 177 177 255 275 504 535 174 174 338 338 Q2 '21 Q2 '22 Q2 '21 Q
Slide 7: Q2 and H1 2022 revenues growth by geography and technology
Q2 and H1 2022 revenues growth by geography and technology Q2’22 vs. H1’22 vs. Q2’22 vs. H1’22 vs. BY GEOGRAPHY BY TECHNOLOGY Q2’21 H1’21 Q2’21 H1’21 EUROPE DIRECT • Positive performance of Immunodiagnostics ex-COVID sales (Latent TB, reported +9.9% +10.0% GI panel, ID panel) and significant contrib
Slide 8: H1 2022 revenues: managerial outlook
H1 2022 revenues: managerial outlook BY GEOGRAPHY BY TECHNOLOGY H1’21 North America Direct Rest of the World H1’21 15.9% 19.8% COVID 34.4% Immunodiagnostics ex-COVID 58.7% Europe Direct COVID 29.9% 34.4% Molecular Diagnostics ex-COVID 6.9% North America Direct 37.5% COVID H1’22 21.8% H1’22 Rest of t
Slide 9: Q2 and H1 2022 profitability profile
Q2 and H1 2022 profitability profile (data in €/mln @ current exchange rates) 36.5% 46.1% 328 249 115 120 The Adjusted EBITDA mainly reflects the growth in revenues, while Q2'21 Q2'22 the decrease in profitability is largely due to the Luminex inclusion in the scope of consolidation and the resultin
Slide 10: FY 2022 Company Guidance
FY 2022 Company Guidance NEW FY 2022 GUIDANCE at 2021 CER: ▪ REVENUES: around +2% vs. FY’21, with COVID revenues at about € 200 million and ex-COVID revenues growing at approx. 24% ▪ ADJUSTED EBITDA* MARGIN: approx. 38% * With reference to the Adjusted EBITDA please refer to the table included in th
Slide 11: Financial schemes
Financial schemes ee *
Slide 12: Income Statement
Income Statement Q2 H1 (Amounts in million of euros) 2021 2022 2021 2022 Net Revenues 248.7 327.8 515.4 685.4 Cost of sales (78.5) (113.1) (160.1) (235.9) Gross profit 170.2 214.7 355.3 449.5 68.4% 65.5% 68.9% 65.6% Sales and marketing expenses (37.9) (73.4) (74.7) (141.9) Research and development c
Slide 13: Adjusted Income Statement
Adjusted Income Statement* Q2 H1 (Amounts in million of euros) 2021 2022 2021 2022 Net Revenues 248.8 327.8 515.4 685.4 Cost of sales (78.5) (113.1) (160.1) (234.3) Gross profit 170.2 214.8 355.3 451.2 68.4% 65.5% 68.9% 65.8% Sales and marketing expenses (37.9) (63.7) (74.7) (123.0) Research and dev
Slide 14: Reconciliation to consolidated financial statements
Reconciliation to consolidated financial statements H1 2021 H1 2022 Gross Fiscal Gross Fiscal Data in €/mln EBITDA2 EBIT Net Profit Data in €/mln EBITDA2 EBIT Net Profit Margin Impact Margin Impact 355.3 231.3 201.9 n.a. 150.0 449.5 263.6 196.7 n.a. 140.8 IFRS Financial Statements Measures IFRS Fina
Slide 15: Balance Sheet
Balance Sheet (Amounts in million of euros) 12/31/2021 06/30/2022 Change Goodwill and intangibles assets 1,943.4 2,092.9 +149.5 Property, plant and equipment 276.2 289.9 +13.7 Other non-current assets 42.6 44.8 +2.2 Net working capital 361.9 407.8 +45.9 Other non-current liabilities (270.2) (286.7)
Slide 16: Cash flow statement
Cash flow statement Q2 H1 (Amounts in million of euros) 2021 2022 2021 2022 Cash and cash equivalents at the beginning of the period 430.0 521.5 339.9 403.0 Cash provided by operating activities 71.9 45.7 173.7 180.1 Cash used in investing activities (26.6) (28.8) (49.6) (51.9) Cash provided/(used)
Slide 17: DiaSorin
DiaSorin